Studies of antihistamines using the wheal and flare technique: How significant are the results?;Étude des antihistaminiques par la technique du « wheal and flare »: Quelle signification faut-il lui accorder?

Revue Francaise d'Allergologie et d'Immunologie Clinique

Volumn 44, Issue 2, 2004, Pages 194-198

  Pauli, G ^a   Frossard, N ^b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Antihistamines; Histamine; Skin tests

Indexed keywords

ANTIHISTAMINIC AGENT;

ALLERGIC URTICARIA; ALLERGY TEST; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; INTRACUTANEOUS TEST; MEDICAL ASSESSMENT; PREDICTION; REVIEW;

EID: 1342300687     PISSN: 03357457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.allerg.2003.11.005     Document Type: Article

References (36)

1. Simons F.E.R., Mc Millan J.L.M., Simons K.J. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine vs placebo: Suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin. Immunol. 86:1990;540-547.
2. Frossard N., Mélac M., Benabdesselam O., Pauli G. Consistency of the efficacy of cetirizine and ebastine on skin reactivity. Ann Allergy Asthma Immunol. 80:1998;61-65.
3. Grant J.A., Danielson L., Rihoux J.P., DeVos C. A double-blind, single dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine vs placebo: suppression of histamine-induced wheal and flare response for 24 hours in healthy male subjects. Allergy. 54:1999;700-707.
4. Devalia J.L., De Vos C., Hanotte F., Baltes E. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy. 56:2001;50-57.
5. Purohit A., Duvernelle C., Mélac M., Pauli G., Frossard N. Twenty-four hours activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol. 86:2001;387-392.
6. Simons F.E.R., Simons K.J. The pharmacology and use of H1-receptor antagonist drugs. N Engl J Med. 330:1994;1663-1670.
7. Simons F.E.R., Murray H.E., Simons K.J. Quantitation of H1-receptor antagonists in skin and serum. J Allergy Clin Immunol. 95:1995;759-764.
8. Simons F.E.R. H1-receptor antagonists: safety issues. Ann Allergy Clin Immunol. 83:1999;481-488.
9. Purohit A., Duvernelle C., Mélac M., Benabdesselam O., Pauli G., Frossard N. Consistency and efficacy of cetirizine (10 mg) vs ebastine (20 mg) at four hours on skin reactivity. Eur J Clin Pharmacol. 55:1999;589-592.
10. Simons F.E.R., Norman A.S., Xiaochen G., Simons K.J. Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol. 110:2002;777-783.
11. Demoly P., Bousquet J., Manderscheid J.C., et al. Precision of skin prick and puncture tests with nine methods. J Allergy Clin Immunol. 88:1991;758-762.
12. 1 profile of second generation antihistamines. Allergy. 55:2000;40-45.
13. Grant J.A., Riethuisen J.M., Moulaert B., DeVos C. A double-blind, randomized, single dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal and flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 88:2002;190-197.
14. Gispert J., Antonijoan R., Barbanoj M., Gich I., Garcia E., Esbri R., et al. Efficacy of ebastine, cetirizine and loratadine in histamine cutaneous challenges. Ann Allergy Asthma Immunol. 89:2002;259-264.
15. Purohit A., Mélac M., Pauli G., Frossard N. Twenty-four hours activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol. 56:2003;. sous presse.
16. Purohit A, Mélac M, Pauli G, Frossard N. Comparative activity of cetirizine and desloratadine on histamine-induced wheal and flare responses over 24 hours. Submitted.
17. Herrera Abarca J.E., Villarreal J.E., Alanis Espinoza F., Carranza Madrigal J., Chavez Madrigal F., Lara Madrigal R. Demonstration of clinical bioequivalence of teldane and feliberal using a biossay with intradermal histamine challenge in healthy volunteers. Gac Med Mex. 130:1994;446-449.
18. Purohit A., Mélac M., Pauli G., Frossard N. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 hours. Br J Clin Pharmacol. 53:2002;250-254.
19. Wood-Baker R., Holgate S.T. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol. 91:1993;1005-1014.
20. Bousquet J., Van Cauwenberge P., et al. Allergic rhinitis and its impact on asthma. ARIA workshop report. J Allergy Clin Immunol. (108 suppl):2001;S147-S334.
21. Frossard N., Lacronique J., Mélac M., Benabdesselam O., Braun J.J., Glasser N., Pauli G. Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy. 52:1997;205-209.
22. Frossard N., Benabdesselam O., Mélac M., Glasser N., Lacronique J., Pauli G. Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. Am J Ther. 5:1998;307-311.
23. Esau S., del Carpio J., Martin J.G. A comparison of the effects of ketotifen and clemastine on cutaneous and airway reactivity to histamine and allergen in atopic asthmatic subjects. J Allergy Clin Immunol. 74:1984;270-274.
24. Town G.I., Holgate S.T. Comparison of the effect of loratadine on the airway and skin response to histamine, methacholine and allergen in subjects with asthma. J Allergy Clin Immunol. 86:1990;886-893.
25. Frossard N., Vital-Durand D., Mounedji N., Valleteau A. Duration of the antihistaminic effect following discontinuation of ebastine. Allergy. 56:2001;553-557.
26. Kopferschmitt-Kubler M.C., Couchot A., Pauli G. Evaluation of the effect of oral cetirizine on antigen-induced immediate asthmatic response. Ann Allergy. 65:1990;501-503.
27. Day J.H., Briscoe M., Rafeiro E., Chapman P., Kramer B. Comparative onset of action and symptom relief with cetirizine, loratadine or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Clin Immunol. 87:2001;474-481.
28. Persi L., Demoly P., Harris A.G., Tisserand B., Michel F.B., Bousquet J. Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. J Allergy Clin Immunol. 103:1999;591-594.
29. Horak F., Stubner P., Zieglmayer R., Kavina A., de Vos C., Burtin B., et al. Controled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol. 125:2001;73-79.
30. Sabbah A., Daele J., Wade A.G., Ben-Soussen P., Attali T.T. Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZO-CET study group. Ann Allergy Asthma Immunol. 83:1999;319-325.
31. Van Cauwenberge P., Juniper E.F. Comparison of the efficacy, safety, and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo, administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 30:2000;891-899.
32. Rédier H., Chanez P., de Vos C., et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol. 90:1992;215-224.
33. Ciprandi G., Bouscaglia S., Pesce G., et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (OR CD54) expression on conjunctival epithelium in both early- and late-phase reations after allergen-specific challenge. J Allergy Clin Immunol. 95:1995;612-621.
34. Campbell A., Chanal I., Carlewski W., Michel F.B., Bousquet J. Reduction of soluble ICAM-1 levels in nasal secretion by H1-blockers in seasonal allergic rhinitis. Allergy. 52:1997;1022-1025.
35. Ciprandi G., Catrullo A., Cerquiti P., Tosca M., Fiorino N., Canonica G.W. Loratadine reduces the expression of ICAM-1. Allergy. 53:1998;545-546.
36. Simons F.E.R., Norman A.S., Xiaochen G., Simons K.J. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol. 107:2001;526-530.